PRNewswire
Singapore, March 5: Veeva Systems (NYSE: VEEV) today announced Veeva CRM Pulse, a data subscription that provides quarterly healthcare professional (HCP) access and multichannel engagement metrics for the life sciences industry. With HCP access data as an input for segmentation, targeting, and engagement planning, Pulse provides immediate value for commercial operations and data analytics teams.
* Delivered quarterly, CRM Pulse is generated from more than 500 million Veeva CRM interactions for the industry's most complete, timely, and accurate HCP access data
Pulse is unique in giving customers HCP data that has:
True Industry Census: Based on global usage of Veeva's leading CRM Suite, Pulse is the most complete, timely, and accurate data set for HCP access.
Unmatched Coverage: Access and engagement metrics by channel are available for more than three million HCPs across 102 specialties and 21 countries.
Aggregated for Data Privacy: HCP metrics are segmented and aggregated by country, specialty, and brick for data privacy.
"Pulse is a breakthrough data product that will greatly improve segmentation and targeting around the globe," said Peter Stark, executive vice president of Veeva Data Cloud. "We look forward to working with our early customers to bring the value of CRM Pulse data to their commercial operations."
Pulse is available for license to Veeva's CRM customers today with 2024 quarterly data covering the United States, Canada, Germany, United Kingdom, France, Italy, Spain, Portugal, Austria, Switzerland, Netherlands, Belgium, Ireland, Hungary, Brazil, Mexico, Australia, New Zealand, South Korea, Taiwan, and Singapore. Quarterly data releases for 2025 will begin this April. Additional countries in Asia and Europe are planned for availability next year.
Veeva CRM Pulse is part of Veeva Data Cloud, which includes Veeva OpenData, Veeva Link, and Veeva Compass. For more information, visit veeva.com/Pulse.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by PRNewswire.will not be responsible in any way for the content of the same)
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor